<iframe src="//www.googletagmanager.com/ns.html?id=GTM-K3L4M3" height="0" width="0" style="display:none;visibility:hidden">

Any other business

Forget about saving British big pharma – it's little pharma we should be helping

Plus: In praise of the high street, and why the Rich List should be a set text for sixth-formers

24 May 2014

9:00 AM

24 May 2014

9:00 AM

Readers in all sorts of places — at the club bar, over a birthday lunch, even along the church pew — had been telling me I was wrong not to subscribe to the ‘save AstraZeneca’ campaign, and too complacent about the future of British science when I wrote: ‘the game is Pfizer’s for the taking, as soon as the price is right’.

Already a subscriber? Log in

Easter flash sale:
10 issues for $1

Subscribe this Easter and get the next 10 issues of the magazine, plus website and app access, all for just $1.

  • Weekly delivery of the magazine
  • Unlimited access to spectator.com.au and app
  • Spectator Australia podcasts and newsletters
  • Full access to spectator.co.uk
Or

Unlock 3 articles a month

REGISTER

You might disagree with half of it, but you’ll enjoy reading all of it. Try your first month for free, then just $2 a week for the remainder of your first year.


Comments

Easter flash sale: 10 issues for $1

Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.

Already a subscriber? Log in

Close